Smith & Nephew plc (SNN) 10-Year Financial Performance & Capital Metrics

SNN • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

AboutSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.Show more

Revenue $5.81B +4.7%
EBITDA $1.24B +29.9%
Net Income $412M +56.7%
EPS (Diluted) 0.94 -21.7%
Gross Margin 69.64% +1.2%
EBITDA Margin 21.29% +24.1%
Operating Margin 11.31% +47.6%
Net Margin 7.09% +49.6%
ROE 7.86% +56.6%
ROIC 6.17% +52.8%
Debt/Equity 0.63 +6.7%
Interest Coverage 3.91 +27.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.3%

✗Weaknesses

✗Shares diluted 100.0% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.32%

5Y2.49%

3Y3.69%

TTM9.95%

Profit (Net Income) CAGR

10Y-1.94%

5Y-7.24%

3Y-7.7%

TTM11.86%

EPS CAGR

10Y-1.74%

5Y-7.12%

3Y-7.82%

TTM14.2%

ROCE

10Y Avg9.05%

5Y Avg5.39%

3Y Avg5.66%

Latest7.94%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	138.62B	362.49	46.71	10.23%	12.07%	13.51%	2.52%	0.68
SNNSmith & Nephew plc	13.96B	32.89	34.99	4.7%	6.88%	14.44%	4.34%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.59B	88.75	20.03	3.85%	10.05%	6.31%	6.5%	0.50
CNMDCONMED Corporation	1.32B	42.55	9.99	5%	4.75%	6.35%	11.68%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	13.23M	0.72	-0.22	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.43M	9.53	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	237.99M	27.75	-3.95	59.99%	-17.06%		0.83%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.63B	4.67B	4.76B	4.9B	5.14B	4.56B	5.21B	5.21B	5.55B	5.81B
Revenue Growth %	0%	0.01%	0.02%	0.03%	0.05%	-0.11%	0.14%	0%	0.06%	0.05%
Cost of Goods Sold+	1.14B	1.27B	1.25B	1.3B	1.34B	1.4B	1.54B	1.54B	1.73B	1.76B
COGS % of Revenue	0.25%	0.27%	0.26%	0.26%	0.26%	0.31%	0.3%	0.3%	0.31%	0.3%
Gross Profit+	3.49B	3.4B	3.52B	3.61B	3.8B	3.16B	3.67B	3.67B	3.82B	4.05B
Gross Margin %	0.75%	0.73%	0.74%	0.74%	0.74%	0.69%	0.7%	0.7%	0.69%	0.7%
Gross Profit Growth %	0.01%	-0.03%	0.04%	0.03%	0.05%	-0.17%	0.16%	0%	0.04%	0.06%
Operating Expenses+	2.86B	2.6B	2.58B	2.74B	2.98B	2.87B	3.08B	3.23B	3.39B	3.39B
OpEx % of Revenue	0.62%	0.56%	0.54%	0.56%	0.58%	0.63%	0.59%	0.62%	0.61%	0.58%
Selling, General & Admin	2.64B	2.03B	2.15B	2.19B	2.31B	2.56B	2.39B	2.44B	2.6B	2.65B
SG&A % of Revenue	0.57%	0.43%	0.45%	0.45%	0.45%	0.56%	0.46%	0.47%	0.47%	0.46%
Research & Development	222M	230M	223M	246M	292M	307M	356M	345M	299M	289M
R&D % of Revenue	0.05%	0.05%	0.05%	0.05%	0.06%	0.07%	0.07%	0.07%	0.05%	0.05%
Other Operating Expenses	0	239M	202M	176M	0	0	0	0	205M	448M
Operating Income+	628M	801M	934M	863M	815M	295M	593M	315M	425M	657M
Operating Margin %	0.14%	0.17%	0.2%	0.18%	0.16%	0.06%	0.11%	0.06%	0.08%	0.11%
Operating Income Growth %	-0.16%	0.28%	0.17%	-0.08%	-0.06%	-0.64%	1.01%	-0.47%	0.35%	0.55%
EBITDA+	1.14B	1.28B	1.39B	1.32B	1.33B	840M	1.16B	863M	952M	1.24B
EBITDA Margin %	0.25%	0.27%	0.29%	0.27%	0.26%	0.18%	0.22%	0.17%	0.17%	0.21%
EBITDA Growth %	-0.04%	0.12%	0.09%	-0.06%	0.01%	-0.37%	0.38%	-0.25%	0.1%	0.3%
D&A (Non-Cash Add-back)	511M	478M	460M	454M	518M	545M	563M	548M	527M	580M
EBIT	622M	1.13B	946M	852M	818M	321M	679M	326M	429M	657M
Net Interest Income+	-39M	-62M	-61M	-51M	-55M	-56M	-74M	-66M	-105M	-149M
Interest Income	11M	6M	6M	8M	10M	6M	6M	14M	34M	19M
Interest Expense	50M	68M	67M	59M	65M	62M	80M	80M	139M	168M
Other Income/Expense	-69M	261M	-55M	-82M	-72M	-49M	-7M	-80M	-135M	-159M
Pretax Income+	559M	1.06B	879M	781M	743M	246M	586M	235M	290M	498M
Pretax Margin %	0.12%	0.23%	0.18%	0.16%	0.14%	0.05%	0.11%	0.05%	0.05%	0.09%
Income Tax+	149M	278M	112M	118M	143M	-202M	62M	12M	27M	86M
Effective Tax Rate %	0.73%	0.74%	0.87%	0.85%	0.81%	1.82%	0.89%	0.95%	0.91%	0.83%
Net Income+	410M	784M	767M	663M	600M	448M	524M	223M	263M	412M
Net Margin %	0.09%	0.17%	0.16%	0.14%	0.12%	0.1%	0.1%	0.04%	0.05%	0.07%
Net Income Growth %	-0.18%	0.91%	-0.02%	-0.14%	-0.1%	-0.25%	0.17%	-0.57%	0.18%	0.57%
Net Income (Continuing)	410M	784M	767M	663M	600M	448M	524M	223M	263M	412M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.92	1.76	1.76	1.52	1.36	1.02	1.20	0.50	1.20	0.94
EPS Growth %	-0.18%	0.91%	0%	-0.14%	-0.11%	-0.25%	0.18%	-0.58%	1.4%	-0.22%
EPS (Basic)	0.92	1.76	1.76	1.52	1.38	1.02	1.20	0.50	1.20	0.94
Diluted Shares Outstanding	436.45M	446.47M	437.55M	437.55M	437.55M	437.55M	438.86M	437.55M	218.44M	438.3M
Basic Shares Outstanding	437.55M	444.95M	437.55M	437.55M	437.55M	437.55M	438.5M	437.55M	217.75M	438.3M
Dividend Payout Ratio	0.66%	0.36%	0.35%	0.48%	0.53%	0.73%	0.63%	1.47%	1.24%	0.79%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.48B	2.53B	2.73B	3.08B	3.22B	4.66B	4.42B	3.86B	4.03B	4.42B
Cash & Short-Term Investments	120M	100M	169M	365M	277M	1.76B	1.29B	350M	302M	619M
Cash Only	120M	100M	169M	365M	277M	1.76B	1.29B	350M	302M	619M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	939M	988M	1.06B	1.1B	1.08B	911M	971M	1.03B	1.06B	1.21B
Days Sales Outstanding	73.96	77.24	80.89	82.17	76.86	72.92	68	71.88	69.66	75.83
Inventory	1.22B	1.24B	1.3B	1.4B	1.61B	1.69B	1.84B	2.21B	2.4B	2.39B
Days Inventory Outstanding	388.63	356.97	381.38	392.28	440.29	442.13	436.2	522.61	505.3	493.91
Other Current Assets	115M	124M	120M	144M	171M	219M	240M	198M	182M	81M
Total Non-Current Assets+	4.69B	4.82B	5.13B	4.98B	6.08B	6.35B	6.5B	6.11B	5.96B	5.93B
Property, Plant & Equipment	932M	982M	1.05B	1.06B	1.32B	1.45B	1.51B	1.46B	1.47B	1.42B
Fixed Asset Turnover	4.97x	4.75x	4.54x	4.62x	3.88x	3.15x	3.44x	3.58x	3.77x	4.09x
Goodwill	2.01B	2.19B	2.37B	2.34B	2.79B	2.93B	2.99B	3.03B	2.99B	3.03B
Intangible Assets	1.5B	1.41B	1.37B	1.21B	1.57B	1.49B	1.4B	1.24B	1.11B	1.03B
Long-Term Investments	128M	137M	201M	231M	216M	250M	380M	58M	24M	16M
Other Non-Current Assets	13M	0	16M	16M	35M	33M	15M	153M	361M	103M
Total Assets+	7.17B	7.34B	7.87B	8.06B	9.3B	11.01B	10.92B	9.97B	9.99B	10.35B
Asset Turnover	0.65x	0.64x	0.61x	0.61x	0.55x	0.41x	0.48x	0.52x	0.56x	0.56x
Asset Growth %	-0.02%	0.02%	0.07%	0.02%	0.15%	0.18%	-0.01%	-0.09%	0%	0.04%
Total Current Liabilities+	1.34B	1.35B	1.35B	1.47B	1.56B	1.69B	2.13B	1.72B	2.27B	1.53B
Accounts Payable	808M	807M	873M	854M	941M	891M	1.04B	1.03B	1.02B	1.08B
Days Payables Outstanding	258.02	231.57	255.32	240.15	256.7	232.96	246.72	243.89	214.36	223.88
Short-Term Debt	44M	85M	29M	167M	26M	279M	435M	111M	710M	2M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	490M	454M	444M	444M	551M	460M	597M	526M	261M	126M
Current Ratio	1.84x	1.88x	2.03x	2.10x	2.06x	2.76x	2.08x	2.25x	1.77x	2.89x
Quick Ratio	0.94x	0.95x	1.06x	1.15x	1.03x	1.76x	1.21x	0.96x	0.72x	1.33x
Cash Conversion Cycle	204.57	202.63	206.94	234.3	260.46	282.09	257.48	350.61	360.6	345.85
Total Non-Current Liabilities+	1.86B	2.04B	1.88B	1.72B	2.59B	4.04B	3.22B	2.99B	2.5B	3.56B
Long-Term Debt	1.43B	1.56B	1.42B	1.3B	1.85B	3.2B	2.71B	2.56B	2.17B	3.12B
Capital Lease Obligations	8M	5M	0	0	124M	157M	141M	147M	144M	135M
Deferred Tax Liabilities	77M	94M	97M	99M	167M	141M	144M	36M	0	0
Other Non-Current Liabilities	423M	474M	453M	419M	619M	692M	373M	280M	180M	300M
Total Liabilities	3.2B	3.39B	3.22B	3.19B	4.16B	5.73B	5.35B	4.71B	4.77B	5.09B
Total Debt+	1.48B	1.65B	1.45B	1.47B	2.05B	3.69B	3.34B	2.87B	3.08B	3.32B
Net Debt	1.36B	1.55B	1.28B	1.1B	1.77B	1.93B	2.05B	2.52B	2.78B	2.7B
Debt / Equity	0.37x	0.42x	0.31x	0.30x	0.40x	0.70x	0.60x	0.55x	0.59x	0.63x
Debt / EBITDA	1.30x	1.29x	1.04x	1.11x	1.54x	4.39x	2.89x	3.33x	3.24x	2.68x
Net Debt / EBITDA	1.19x	1.21x	0.92x	0.84x	1.33x	2.30x	1.77x	2.92x	2.92x	2.18x
Interest Coverage	12.56x	11.78x	13.94x	14.63x	12.54x	4.76x	7.41x	3.94x	3.06x	3.91x
Total Equity+	3.97B	3.96B	4.64B	4.87B	5.14B	5.28B	5.57B	5.26B	5.22B	5.26B
Equity Growth %	-0.02%	-0%	0.17%	0.05%	0.05%	0.03%	0.05%	-0.06%	-0.01%	0.01%
Book Value per Share	9.09	8.87	10.61	11.14	11.75	12.06	12.69	12.02	23.88	12.01
Total Shareholders' Equity	3.97B	3.96B	4.64B	4.87B	5.14B	5.28B	5.57B	5.26B	5.22B	5.26B
Common Stock	183M	180M	178M	177M	177M	177M	177M	175M	175M	175M
Retained Earnings	3.73B	3.97B	4.33B	4.63B	4.85B	4.96B	5.22B	5.03B	4.91B	5.02B
Treasury Stock	-294M	-432M	-257M	-214M	-189M	-157M	-120M	-118M	-94M	-66M
Accumulated OCI	-244M	-360M	-211M	-322M	-306M	-311M	-328M	-439M	-385M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.03B	849M	1.09B	931M	1.17B	935M	877M	468M	608M	987M
Operating CF Margin %	0.22%	0.18%	0.23%	0.19%	0.23%	0.21%	0.17%	0.09%	0.11%	0.17%
Operating CF Growth %	0.51%	-0.18%	0.28%	-0.15%	0.25%	-0.2%	-0.06%	-0.47%	0.3%	0.62%
Net Income	559M	1.06B	879M	781M	743M	246M	586M	235M	290M	412M
Depreciation & Amortization	511M	478M	460M	454M	518M	596M	581M	628M	527M	580M
Stock-Based Compensation	29M	27M	31M	35M	32M	26M	41M	40M	39M	40M
Deferred Taxes	-176M	-594M	-229M	-201M	-207M	-50M	-255M	0	0	0
Other Non-Cash Items	38M	46M	51M	51M	55M	56M	74M	100M	84M	78M
Working Capital Changes	69M	-170M	-102M	-189M	27M	61M	-150M	-535M	-332M	-123M
Change in Receivables	-26M	-74M	-40M	-108M	30M	209M	-81M	-103M	-49M	-81M
Change in Inventory	-83M	-47M	-17M	-152M	-204M	-45M	-151M	-407M	-178M	-42M
Change in Payables	0	0	0	0	-30M	-209M	81M	103M	0	0
Cash from Investing+	-429M	-383M	-543M	-378M	-1.25B	-606M	-691M	-472M	-448M	-569M
Capital Expenditures	-358M	-392M	-376M	-347M	-408M	-443M	-408M	-358M	-427M	-381M
CapEx % of Revenue	0.08%	0.08%	0.08%	0.07%	0.08%	0.1%	0.08%	0.07%	0.08%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-358M	-392M	-376M	-345M	26M	7M	-404M	1M	0	-2M
Cash from Financing+	-558M	-529M	-434M	-371M	7M	1.16B	-645M	-926M	-200M	-86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-272M	-279M	-269M	-321M	-318M	-328M	-329M	-327M	-327M	-327M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-15M	-9M	24M	-14M	-37M	-37M	-63M	-51M	-48M	-55M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	672M	457M	714M	584M	760M	492M	469M	110M	181M	606M
FCF Margin %	0.15%	0.1%	0.15%	0.12%	0.15%	0.11%	0.09%	0.02%	0.03%	0.1%
FCF Growth %	1.18%	-0.32%	0.56%	-0.18%	0.3%	-0.35%	-0.05%	-0.77%	0.65%	2.35%
FCF per Share	1.54	1.02	1.63	1.33	1.74	1.12	1.07	0.25	0.83	1.38
FCF Conversion (FCF/Net Income)	2.51x	1.08x	1.42x	1.40x	1.95x	2.09x	1.67x	2.10x	2.31x	2.40x
Interest Paid	0	0	0	0	0	0	0	0	0	140M
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.24%	19.79%	17.83%	13.93%	11.98%	8.6%	9.66%	4.12%	5.02%	7.86%
Return on Invested Capital (ROIC)	8.58%	11.09%	12.25%	10.88%	9.49%	3.13%	6%	3.07%	4.04%	6.17%
Gross Margin	75.33%	72.76%	73.81%	73.53%	73.96%	69.39%	70.4%	70.47%	68.82%	69.64%
Net Margin	8.85%	16.79%	16.1%	13.52%	11.68%	9.82%	10.05%	4.28%	4.74%	7.09%
Debt / Equity	0.37x	0.42x	0.31x	0.30x	0.40x	0.70x	0.60x	0.55x	0.59x	0.63x
Interest Coverage	12.56x	11.78x	13.94x	14.63x	12.54x	4.76x	7.41x	3.94x	3.06x	3.91x
FCF Conversion	2.51x	1.08x	1.42x	1.40x	1.95x	2.09x	1.67x	2.10x	2.31x	2.40x
Revenue Growth	0.37%	0.76%	2.06%	2.92%	4.77%	-11.25%	14.3%	0.06%	6.4%	4.7%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Orthopaedics, Sports Medicine and ENT and Advanced Wound Management	-	-	-	-	5.21B	5.21B	5.55B	5.81B
Orthopaedics, Sports Medicine and ENT and Advanced Wound Management Growth	-	-	-	-	-	0.06%	6.40%	4.70%
Orthopaedics, Sports Medicine and Ear Nose and Throat	-	-	-	-	3.72B	3.7B	3.94B	4.13B
Orthopaedics, Sports Medicine and Ear Nose and Throat Growth	-	-	-	-	-	-0.35%	6.48%	4.72%
Advanced Wound Management	-	1.27B	1.38B	1.31B	1.5B	1.51B	1.61B	1.68B
Advanced Wound Management Growth	-	-	8.24%	-5.07%	14.20%	1.07%	6.22%	4.67%
Orthopaedics Sports Medicine And Ent And Advanced Wound Management	-	-	5.14B	4.56B	-	-	-	-
Orthopaedics Sports Medicine And Ent And Advanced Wound Management Growth	-	-	-	-11.25%	-	-	-	-
Orthopaedics Sports Medicine And Ear Nose And Throat	-	-	3.76B	3.25B	-	-	-	-
Orthopaedics Sports Medicine And Ear Nose And Throat Growth	-	-	-	-13.52%	-	-	-	-
Reconstruction Sports Medicine Trauma And Other Surgical Businesses	-	3.63B	-	-	-	-	-	-
Reconstruction Sports Medicine Trauma And Other Surgical Businesses Growth	-	-	-	-	-	-	-	-
Knee Implants	615M	1.02B	-	-	-	-	-	-
Knee Implants Growth	-	65.37%	-	-	-	-	-	-
Advanced Wound Care	720M	740M	-	-	-	-	-	-
Advanced Wound Care Growth	-	2.78%	-	-	-	-	-	-
Sports Medicine Joint Repair	984M	697M	-	-	-	-	-	-
Sports Medicine Joint Repair Growth	-	-29.17%	-	-	-	-	-	-
Hip Implants	189M	613M	-	-	-	-	-	-
Hip Implants Growth	-	224.34%	-	-	-	-	-	-
Arthroscopic Enabling Technologies	599M	600M	-	-	-	-	-	-
Arthroscopic Enabling Technologies Growth	-	0.17%	-	-	-	-	-	-
Trauma Extremities	495M	493M	-	-	-	-	-	-
Trauma Extremities Growth	-	-0.40%	-	-	-	-	-	-
Advanced Wound Bioactives	342M	320M	-	-	-	-	-	-
Advanced Wound Bioactives Growth	-	-6.43%	-	-	-	-	-	-
Advanced Wound Devices	194M	215M	-	-	-	-	-	-
Advanced Wound Devices Growth	-	10.82%	-	-	-	-	-	-
Other Surgical Businesses	627M	209M	-	-	-	-	-	-
Other Surgical Businesses Growth	-	-66.67%	-	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023	2024
United States of America	-	-	-	-	2.66B	2.76B	-	-
United States of America Growth	-	-	-	-	-	3.99%	-	-
China	-	-	-	-	352M	319M	-	-
China Growth	-	-	-	-	-	-9.38%	-	-
U	2.33B	2.35B	2.55B	2.34B	-	-	-	-
U Growth	-	0.94%	8.37%	-8.31%	-	-	-	-
C	-	-	336M	318M	-	-	-	-
C Growth	-	-	-	-5.36%	-	-	-	-
G	244M	211M	211M	166M	-	-	-	-
G Growth	-	-13.52%	0.00%	-21.33%	-	-	-	-
Rest Of World Excluding United Kingdom And United States Of America	2.19B	-	-	-	-	-	-	-
Rest Of World Excluding United Kingdom And United States Of America Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Smith & Nephew plc (SNN) has a price-to-earnings (P/E) ratio of 35.0x. This suggests investors expect higher future growth.

Growth & Financials

Smith & Nephew plc (SNN) reported $11.61B in revenue for fiscal year 2024. This represents a 172% increase from $4.27B in 2011.

Smith & Nephew plc (SNN) grew revenue by 4.7% over the past year. Growth has been modest.

Yes, Smith & Nephew plc (SNN) is profitable, generating $798.6M in net income for fiscal year 2024 (7.1% net margin).

Dividend & Returns

Yes, Smith & Nephew plc (SNN) pays a dividend with a yield of 2.27%. This makes it attractive for income-focused investors.

Smith & Nephew plc (SNN) has a return on equity (ROE) of 7.9%. This is below average, suggesting room for improvement.

Smith & Nephew plc (SNN) generated $1.10B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...